home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2805.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
42 lines
Document 2805
DOCN M94A2805
TI Immunotherapy with autologous HIV-specific CTL.
DT 9412
AU Lieberman J; Fabry JA; Skolnik PR; Parkerson GR; Fong DM; Kagan J;
Standiford H; Lee E; Landry B; New England Medical Center, Boston, MA
02111.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):220 (abstract no. PB0311). Unique
Identifier : AIDSLINE ICA10/94369770
AB OBJECTIVE: To test the feasibility, safety and tolerance of treating
patients with CD4 counts of 100-400/mm3 by infusion of HIV-specific CTL
in an attempt to bolster host immunity to control the virus. METHODS:
The CTL response to HIV-1 is dominated by the recognition of a small
number of peptides encoded by HIV-1 structural and regulatory genes. We
are able to expand selectively HIV-specific CTL ex vivo by culture with
autologous antigen-presenting cells preincubated with immunodominant
HIV-1 peptides. In this pilot trial, groups of 5-8 patients are treated
by a single infusion of 1 or 5 billion CTL, selectively expanded to
recognize and lyse HIV-expressing targets, and followed for 6 months as
to clinical course, T cell counts, viral burden in the blood, surrogate
markers of infection and HIV-specific cellular immunity. RESULTS: In the
first 9 patients followed for up to 6 months, no toxicity was associated
with the infusion. Preliminary data reveal a rise in HIV-specific
peripheral blood CTL in most patients. Following treatment some patients
show CTL activity to previously unrecognized HIV proteins. Data will be
presented about changes in viral titers in the peripheral blood as well
as in surrogate markers of disease including CD4 counts. CONCLUSIONS:
Immunotherapy with ex vivo-expanded autologous HIV-specific CTL is safe
and feasible. Because of preliminary encouraging results, we are
currently planning to reinfuse treated patients and to treat another
cohort with multiple infusions.
DE *Blood Transfusion, Autologous Cells, Cultured/TRANSPLANTATION Cohort
Studies Feasibility Studies Follow-Up Studies Human HIV
Infections/IMMUNOLOGY/*THERAPY HIV-1/*IMMUNOLOGY Immunodominant
Epitopes/IMMUNOLOGY *Immunotherapy, Adoptive Leukapheresis Leukocyte
Count Pilot Projects Safety T-Lymphocytes,
Cytotoxic/IMMUNOLOGY/*TRANSPLANTATION T4 Lymphocytes MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).